Clinical Trial Finds An Increased Risk Of Blood Clots In The Lungs And Of Death In Rheumatoid Arthritis Patients Taking High Dose Of Tofacitinib (sold As Xeljanz Or Xeljanz Xr)
Recall Summary A clinical trial found that rheumatoid arthritis patients taking high doses of tofacitinib (Xeljanz or Xeljanz XR) had an increased risk of blood clots in the lungs and death compared to those on other treatments. This safety concern affects the product across Canada. The recall applies to high-dose tofacitinib used for rheumatoid arthritis.
- Reason
- Product safety
- Category
- consumer product recall
- Country
- Canada
- Agency
- HC-PRODUCTS
- Recall date
- 2019-03-15
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-PRODUCTS
Recall details on Nibble Recalls: https://trynibble.app/recalls/6baf4678-d4e7-41a7-9e85-971cb9016f82